U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Papulopustular Rash

MedGen UID:
388569
•Concept ID:
C2609319
•
Sign or Symptom

Definition

Skin eruption consisting of papules and pustules, most often appearing in the face, scalp, and upper trunk. It is usually caused by corticosteroids or epidermal growth factor receptor inhibitors. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVPapulopustular Rash

Professional guidelines

PubMed

EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines.
Nowaczyk J, Fret K, Kaminska-Winciorek G, Rudnicka L, Czuwara J
Anticancer Drugs 2023 Sep 1;34(8):942-948. Epub 2023 Jan 24 doi: 10.1097/CAD.0000000000001494. PMID: 36708507Free PMC Article
Clinical features and treatment of epidermal growth factor inhibitor-related late-phase papulopustular rash.
Tohyama M, Hamada M, Harada D, Kozuki T, Nogami N, Monden N, Kajiwara T, Nishina T
J Dermatol 2020 Feb;47(2):121-127. Epub 2019 Dec 5 doi: 10.1111/1346-8138.15170. PMID: 31803963
Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities.
Chu CY, Chen KY, Wen-Cheng Chang J, Wei YF, Lee CH, Wang WM
J Formos Med Assoc 2017 Jun;116(6):413-423. Epub 2017 Mar 27 doi: 10.1016/j.jfma.2017.03.001. PMID: 28351555

Recent clinical studies

Etiology

Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
Yalici-Armagan B, Ayanoglu BT, Demirdag HG
Cutan Ocul Toxicol 2019 Sep;38(3):261-266. Epub 2019 May 7 doi: 10.1080/15569527.2019.1594874. PMID: 31010330
Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors.
Hofheinz RD, Segaert S, Safont MJ, Demonty G, Prenen H
Crit Rev Oncol Hematol 2017 Jun;114:102-113. Epub 2017 Apr 11 doi: 10.1016/j.critrevonc.2017.03.032. PMID: 28477738
Managing skin toxicities related to panitumumab.
Bergman H, Walton T, Del Bel R, Seki JT, Rafii A, Xu W, Koren G, Shear N, Krzyzanowska MK, Howell D, Liu G
J Am Acad Dermatol 2014 Oct;71(4):754-9. Epub 2014 Jul 29 doi: 10.1016/j.jaad.2014.06.011. PMID: 25085331
Adverse events to nontargeted and targeted chemotherapeutic agents: emphasis on hypersensitivity responses.
Baldo BA, Pagani M
Immunol Allergy Clin North Am 2014 Aug;34(3):565-96, viii. doi: 10.1016/j.iac.2014.04.003. PMID: 25017678
Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions.
Curry JL, Torres-Cabala CA, Kim KB, Tetzlaff MT, Duvic M, Tsai KY, Hong DS, Prieto VG
Int J Dermatol 2014 Mar;53(3):376-84. Epub 2013 Jul 24 doi: 10.1111/ijd.12205. PMID: 23879247

Diagnosis

Papulopustular Rash in Behçet's Disease.
Finazzi A, Cosentini R
N Engl J Med 2023 Mar 9;388(10):e30. Epub 2023 Mar 4 doi: 10.1056/NEJMicm2209759. PMID: 36876757
An eosinophilic papulopustular rash in a baby.
Plzáková Z, Bloomfield M, Polášková S, Štork J, Honzík T
Pediatr Dermatol 2020 Jul;37(4):e32-e34. doi: 10.1111/pde.14164. PMID: 32706466
Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
Yalici-Armagan B, Ayanoglu BT, Demirdag HG
Cutan Ocul Toxicol 2019 Sep;38(3):261-266. Epub 2019 May 7 doi: 10.1080/15569527.2019.1594874. PMID: 31010330
Hyper-IgE Syndrome in an Infant.
Giberson M, Finlayson L
J Cutan Med Surg 2016 Jul;20(4):340-2. Epub 2016 Jan 22 doi: 10.1177/1203475416629593. PMID: 26801049
Adverse events to nontargeted and targeted chemotherapeutic agents: emphasis on hypersensitivity responses.
Baldo BA, Pagani M
Immunol Allergy Clin North Am 2014 Aug;34(3):565-96, viii. doi: 10.1016/j.iac.2014.04.003. PMID: 25017678

Therapy

Clinical features and treatment of epidermal growth factor inhibitor-related late-phase papulopustular rash.
Tohyama M, Hamada M, Harada D, Kozuki T, Nogami N, Monden N, Kajiwara T, Nishina T
J Dermatol 2020 Feb;47(2):121-127. Epub 2019 Dec 5 doi: 10.1111/1346-8138.15170. PMID: 31803963
Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
Yalici-Armagan B, Ayanoglu BT, Demirdag HG
Cutan Ocul Toxicol 2019 Sep;38(3):261-266. Epub 2019 May 7 doi: 10.1080/15569527.2019.1594874. PMID: 31010330
Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors.
Hofheinz RD, Segaert S, Safont MJ, Demonty G, Prenen H
Crit Rev Oncol Hematol 2017 Jun;114:102-113. Epub 2017 Apr 11 doi: 10.1016/j.critrevonc.2017.03.032. PMID: 28477738
Subantimicrobial-dose doxycycline monohydrate in dermatology.
Wollina U
Wien Med Wochenschr 2015 Dec;165(23-24):499-503. Epub 2015 Nov 13 doi: 10.1007/s10354-015-0399-9. PMID: 26564206
Adverse events to nontargeted and targeted chemotherapeutic agents: emphasis on hypersensitivity responses.
Baldo BA, Pagani M
Immunol Allergy Clin North Am 2014 Aug;34(3):565-96, viii. doi: 10.1016/j.iac.2014.04.003. PMID: 25017678

Prognosis

EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines.
Nowaczyk J, Fret K, Kaminska-Winciorek G, Rudnicka L, Czuwara J
Anticancer Drugs 2023 Sep 1;34(8):942-948. Epub 2023 Jan 24 doi: 10.1097/CAD.0000000000001494. PMID: 36708507Free PMC Article
Clinical features and treatment of epidermal growth factor inhibitor-related late-phase papulopustular rash.
Tohyama M, Hamada M, Harada D, Kozuki T, Nogami N, Monden N, Kajiwara T, Nishina T
J Dermatol 2020 Feb;47(2):121-127. Epub 2019 Dec 5 doi: 10.1111/1346-8138.15170. PMID: 31803963
Managing skin toxicities related to panitumumab.
Bergman H, Walton T, Del Bel R, Seki JT, Rafii A, Xu W, Koren G, Shear N, Krzyzanowska MK, Howell D, Liu G
J Am Acad Dermatol 2014 Oct;71(4):754-9. Epub 2014 Jul 29 doi: 10.1016/j.jaad.2014.06.011. PMID: 25085331
Skin toxicities associated with epidermal growth factor receptor inhibitors.
Li T, Perez-Soler R
Target Oncol 2009 Apr;4(2):107-19. Epub 2009 May 19 doi: 10.1007/s11523-009-0114-0. PMID: 19452131
Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
Peréz-Soler R, Saltz L
J Clin Oncol 2005 Aug 1;23(22):5235-46. doi: 10.1200/JCO.2005.00.6916. PMID: 16051966

Clinical prediction guides

Clinical features and treatment of epidermal growth factor inhibitor-related late-phase papulopustular rash.
Tohyama M, Hamada M, Harada D, Kozuki T, Nogami N, Monden N, Kajiwara T, Nishina T
J Dermatol 2020 Feb;47(2):121-127. Epub 2019 Dec 5 doi: 10.1111/1346-8138.15170. PMID: 31803963
Skin Manifestations of Targeted Antineoplastic Therapy.
Sanmartín O
Curr Probl Dermatol 2018;53:93-104. Epub 2017 Nov 7 doi: 10.1159/000479198. PMID: 29131041
Monoclonal antibody-induced papulopustular rash: Clinical course, communication to health-care professionals and reactive measures as reported by patients.
Cignola S, Gonella S, Alessandra B, Palese A
Eur J Oncol Nurs 2016 Feb;20:133-9. Epub 2015 Jul 15 doi: 10.1016/j.ejon.2015.07.003. PMID: 26187661
Non-rash skin toxicities associated with novel targeted therapies.
Lacouture ME, Boerner SA, Lorusso PM
Clin Lung Cancer 2006 Dec;8 Suppl 1:S36-42. doi: 10.3816/clc.2006.s.012. PMID: 17239289
Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
Peréz-Soler R, Saltz L
J Clin Oncol 2005 Aug 1;23(22):5235-46. doi: 10.1200/JCO.2005.00.6916. PMID: 16051966

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...